Clinical trial · Observational
Developing Breast (Cancer) Organoids
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Currently, only a few validated biomarkers and models exist guiding or predicting treatment response for specific patient groups. Therefore, a patient-tailored clinical model needs to be developed to address tumour heterogeneity and thereby guide treatment selection on an individualized level. Organoids are patient-derived aggregates that grow in 3D and maintain self- renewal pluripotency and lineage-specific differentiation. Therefore, in contrast with conventional cell lines, they are thought to sustain patient heterogeneity and characteristics and are consequently already in use for drug response screening. This now offers the opportunity to investigate if the primary patient breast cancer organoid platform reflects disease progression, treatment response and relapse in patients with different clinical breast cancer subtypes. Goal: To develop a living biobank from prospective patient-derived breast cancer tissue. The questions we will address are: 1. Do patient-derived breast cancer organoids retain the clinical behaviour and characteristics of the primary patient tumour? 2. Can BC organoids be used to derive prognostic and predictive biomarkers to inform treatment decisions? 3. Can the investigators utilize BC organoids to discover novel actionable targets and combination treatments for therapeutic intervention for breast cancer patients? 4. Can BC organoids be used to discover mechanisms of treatment resistance and relapse?
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Not an extra intervention, tissue taken in routine practice will be used. | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- All patients
- description
- The is only 1 arm: all breast cancer patients undergoing surgery.
- interventionNames
- Other: Not an extra intervention, tissue taken in routine practice will be used.
Primary outcomes (1)
- measure
- Living biobank
- timeFrame
- 12 months
- description
- The development of a patient derived breast cancer living biobank using 3D organoid technology reflecting the most prominent clinical subtypes.
Secondary outcomes (1)
- measure
- Organoids.
- timeFrame
- 12 months
- description
- Cultivate breast cancer organoids that can be used to predict the treatment response to existing and novel combination treatments.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Female, * \>18 years, * Family Anamneses * Breast cancer (proven by histopathology), Included subtypes; (ER-,PR- HER2-); (ER+, PR+, HER2-); (ER+, PR+ HER2+). * Primary surgery (lumpectomy or mastectomy) Exclusion Criteria: \- Physically or mentally incapable or incompetent to sign informed consent
References
Publications (0)
Data not yet available